Skip to main content

Hidradenitis Suppurativa News

Findings from a recent study showed patients with hidradenitis suppurativa experienced significant delays in receiving a diagnosis, and these delays were associated with more severe disease burden.
A recent poster study, presented at AAD VMX 2020, showed that adalimumab effectively reduced hidradenitis suppurativa activity among patients at an outpatient dermatology center.
Findings from a recent study showed major depressive disorder was associated with an increased risk of autoimmune skin diseases, including hidradenitis suppurativa.
Findings from a recent study indicated that several comorbidities precede a diagnosis of hidradenitis suppurativa, and that several develop afterwards.
Findings from an open label cohort study showed treatment of moderate to severe hidradenitis suppurativa with an IL-17 inhibitor was associated clinical response and had a favorable safety profile.
Findings from a recent study showed a potential association between birth weight and childhood weight and the risk of developing hidradenitis suppurativa in adulthood.
In a recent study, researchers assessed the prevalence of inflammatory eye disease and treatment outcomes among patients with hidradenitis suppurativa.
A recent systemic review showed patients with hidradenitis suppurativa who underwent partial excision had higher recurrence rates compared with wide excision.
A recent study showed only 32% of patients with hidradenitis suppurativa who are overweight or obese receive weight counseling, which suggests more awareness and education about weight management and nutrition among this patient population.
A recent study identified a possible ‘window of opportunity’ for initiating adalimumab that could predict treatment response among patients with hidradenitis suppurativa.
Back to Top